Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIVI NASDAQ:CNSP OTCMKTS:EMMA NASDAQ:ENTO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$1.60+5.3%$6.74$1.46▼$75.00$12.05M0.7425,663 shs187,117 shsCNSPCNS Pharmaceuticals$6.48+6.8%$8.76$4.93▼$221.94$3.72M2.6479,992 shs79,137 shsEMMAEmmaus Life Sciences$0.01+5.0%$0.01$0.00▼$0.05$800K8.0327,516 shs500 shsENTOEntero Therapeutics$2.04+0.5%$1.49$0.84▼$2.78$3.24M0.85.23 million shs163,315 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie0.00%-3.03%-78.81%-84.47%-95.32%CNSPCNS Pharmaceuticals0.00%+27.31%-24.56%-50.91%-93.49%EMMAEmmaus Life Sciences0.00%-19.35%-18.30%-3.85%+316.67%ENTOEntero Therapeutics0.00%+11.48%+40.47%+78.99%+61.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIVIBioVie0.3519 of 5 stars0.04.00.00.00.60.00.6CNSPCNS Pharmaceuticals1.4591 of 5 stars3.32.00.00.01.30.00.6EMMAEmmaus Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AENTOEntero TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie 4.00Strong BuyN/AN/ACNSPCNS Pharmaceuticals 2.50Moderate Buy$300.004,529.63% UpsideEMMAEmmaus Life Sciences 0.00N/AN/AN/AENTOEntero Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$2.52 per shareN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/A$22.84 per shareN/AEMMAEmmaus Life Sciences$16.65M0.05N/AN/A($0.87) per share-0.01ENTOEntero TherapeuticsN/AN/AN/AN/A($3.96) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$17.54M-$79.10N/A∞N/AN/A-89.02%-75.32%9/29/2025 (Estimated)CNSPCNS Pharmaceuticals-$14.86M-$3,748.50N/A∞N/AN/A-183.89%-139.37%N/AEMMAEmmaus Life Sciences-$6.45M-$0.10N/A∞N/A-24.20%N/A-14.00%N/AENTOEntero Therapeutics-$18.06MN/A0.00∞N/AN/A-1,063.82%-17.94%11/11/2025 (Estimated)Latest EMMA, CNSP, ENTO, and BIVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CNSPCNS Pharmaceuticals-$9.60-$6.42+$3.18-$6.42N/AN/A8/14/2025Q2 2025EMMAEmmaus Life SciencesN/A-$0.02N/A-$0.02N/A$2.82 million8/14/2025Q2 2025ENTOEntero TherapeuticsN/A-$0.42N/A-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AN/AEMMAEmmaus Life SciencesN/AN/AN/AN/AN/AENTOEntero TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A9.109.31CNSPCNS PharmaceuticalsN/A10.224.94EMMAEmmaus Life SciencesN/A0.080.06ENTOEntero TherapeuticsN/A2.812.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%CNSPCNS Pharmaceuticals14.02%EMMAEmmaus Life Sciences7.42%ENTOEntero Therapeutics12.30%Insider OwnershipCompanyInsider OwnershipBIVIBioVie2.39%CNSPCNS Pharmaceuticals0.07%EMMAEmmaus Life Sciences35.00%ENTOEntero Therapeutics0.75%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie107.53 million7.35 millionNo DataCNSPCNS Pharmaceuticals5570,000575,000Not OptionableEMMAEmmaus Life Sciences6063.87 million41.51 millionNot OptionableENTOEntero Therapeutics91.59 million1.58 millionN/AEMMA, CNSP, ENTO, and BIVI HeadlinesRecent News About These CompaniesEntero Therapeutics Inc trading halted, news pendingAugust 16, 2025 | msn.comEntero Therapeutics stock falls after announcing reverse stock splitAugust 14, 2025 | investing.comEntero Therapeutics, Inc. Announces Reverse Stock Split | ENTO Stock NewsAugust 14, 2025 | gurufocus.comEntero Therapeutics, Inc. Announces Reverse Stock SplitAugust 14, 2025 | newsfilecorp.comNEntero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq RulesAugust 11, 2025 | newsfilecorp.comNEntero Therapeutics regains Nasdaq compliance after annual meetingJuly 9, 2025 | investing.comEntero Therapeutics Inc ENTOJune 20, 2025 | morningstar.comMFluroTech Ltd. Announces Change in DirectorsJune 13, 2025 | newsfilecorp.comNEntero Therapeutics Delays 10-K FilingApril 1, 2025 | tipranks.comEntero Therapeutics slips 7%, signs rescission agreement with ImmunogenXMarch 25, 2025 | msn.comEntero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLCMarch 24, 2025 | newsfilecorp.comNEntero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLCMarch 24, 2025 | newsfilecorp.comNEntero Therapeutics, Inc.: Entero Therapeutics Appoints Richard Paolone as CEOFebruary 15, 2025 | finanznachrichten.deEntero Therapeutics names Richard Paolone interim CEOFebruary 14, 2025 | msn.comEntero Therapeutics names Richard Paolone as interim CEOFebruary 14, 2025 | markets.businessinsider.comEntero Therapeutics Appoints Richard Paolone as CEOFebruary 14, 2025 | globenewswire.comEntero Therapeutics secures $2M revolving loan, appoints three new directorsFebruary 8, 2025 | markets.businessinsider.comEntero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board MembersFebruary 7, 2025 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Entero ...November 15, 2024 | bakersfield.comB$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Entero Therapeutics, Inc. – ENTONovember 15, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Why the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025Deere’s Sell-Off Could Be a Long-Term Buying ChanceBy Chris Markoch | August 14, 2025EMMA, CNSP, ENTO, and BIVI Company DescriptionsBioVie NASDAQ:BIVI$1.60 +0.08 (+5.26%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.63 +0.03 (+1.87%) As of 08/22/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.CNS Pharmaceuticals NASDAQ:CNSP$6.48 +0.41 (+6.75%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$6.05 -0.43 (-6.64%) As of 08/22/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Emmaus Life Sciences OTCMKTS:EMMA$0.01 +0.00 (+5.04%) As of 08/22/2025 03:45 PM EasternEmmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.Entero Therapeutics NASDAQ:ENTO$2.04 +0.01 (+0.49%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.04 +0.00 (+0.25%) As of 08/22/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access